Mirati Therapeutics - MRTX Stock Forecast, Price & News

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" MRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRTX, but not buy additional shares or sell existing shares.
View MRTX analyst ratings or view top-rated stocks.

13 Wall Street research analysts have issued 1-year price targets for Mirati Therapeutics' shares. Their MRTX share price forecasts range from $50.00 to $188.00. On average, they anticipate the company's stock price to reach $80.87 in the next year. This suggests a possible upside of 117.5% from the stock's current price.
View analysts price targets for MRTX or view top-rated stocks among Wall Street analysts.

Mirati Therapeutics' stock was trading at $45.31 at the beginning of 2023. Since then, MRTX stock has decreased by 17.9% and is now trading at $37.18.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our MRTX earnings forecast.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) posted its quarterly earnings data on Tuesday, February, 28th. The biotechnology company reported ($3.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.74) by $0.23. The biotechnology company had revenue of $0.93 million for the quarter, compared to analysts' expectations of $2.65 million. Mirati Therapeutics had a negative net margin of 5,957.44% and a negative trailing twelve-month return on equity of 66.05%. Mirati Therapeutics's revenue for the quarter was up 212.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($3.72) EPS.

ETFs with the largest weight of Mirati Therapeutics (NASDAQ:MRTX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), IQ U.S. Mid Cap R&D Leaders ETF (MRND), Principal Healthcare Innovators ETF (BTEC), BlackRock Future Health ETF (BMED) and Invesco Nasdaq Biotechnology ETF (IBBQ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU).

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

Shares of MRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MRTX stock can currently be purchased for approximately $37.18.

Mirati Therapeutics (NASDAQ:MRTX) has a market capitalization of $2.16 billion and generates $12.44 million in revenue each year. The biotechnology company earns $-740,870,000.00 in net income (profit) each year or ($13.18) on an earnings per share basis.

The company employs 413 workers across the globe.

Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.mirati.com. The biotechnology company can be reached via phone at (858) 332-3410 or via email at ir@mirati.com.